Showing 4381-4390 of 7169 results for "".
- Experimental Drug May Reverse Hair Loss, Hair Whitening and Skin Inflammationhttps://practicaldermatology.com/news/experimental-drug-may-reverse-hair-loss-hair-whitening-and-skin-inflammation/2457669/An experimental drug can successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol, according to a new Johns Hopkins study in mice. The investigators say the compound halts the production of glycosphingolipi
- SENTÉ Launches Dermal Contour Pressed Serumhttps://practicaldermatology.com/news/sent-launches-dermal-contour-pressed-serum/2457670/Senté's Dermal Contour Pressed Serum with 3 glycosaminoglycan analogs to help tighten skin for a more youthful contour is now availalbe. Patented Heparan Sulfate Analog (HSA) combined with Dermatan Sulfate Analog (DSA) and Chondroitin, Sulfate Analog (CSA), the company's proprietar
- Almirall: Phase 3 Studies of KX2-391 for AK Meet Primary Endpointshttps://practicaldermatology.com/news/almirall-phase-3-studies-of-kx2-391-for-ak-meet-primary-endpoints/2457676/Both Phase 3 studies of KX2-391met the primary endpoint of complete clearance of actinic keratosis (AK) lesions at day 57 within the face or scalp treatment areas, Almirall, SA reports. Each study achieved statistical significance on this endpoint. The double-blind, randomized, vehi
- iRestore Expands Reseller Programhttps://practicaldermatology.com/news/irestore-expands-reseller-program/2457677/The iRestore Laser Hair Growth System from Freedom Laser Therapy is now more widely available, thanks to an expanded reseller program for the drug-free, pain-free laser hair restoration device. The reseller program now offers an affiliate model that enables sales representative
- Colorescience Receives Patent for Even Up Clinical Pigment Corrector Formulationhttps://practicaldermatology.com/news/colorescience-receives-patent-for-even-up-clinical-pigment-corrector-formulation/2457687/The US Patent and Trademark Office (USPTO) has granted a patent for Colorescience’s LUMIRA™ formulation, a clinically tested, highly effective complex that addresses the appearance of skin discoloration, found in the 3-in-1 treatment product, Even Up® Clinical Pigment P
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- Novartis Enters Licensing Deal for IL-17C Compound for Atopic Dermatitishttps://practicaldermatology.com/news/novartis-enters-licensing-deal-for-il-17c-compound-for-atopic-dermatitis/2457689/Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) to acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Novarti
- Life Sciences Industry Eyes $1.5 Trillion Milestonehttps://practicaldermatology.com/news/life-sciences-industry-eyes-15-trillion-milestone/2457703/The life sciences industry is nearing a $1.5 trillion milestone, according to an analysis from Frost & Sullivan. The firm’s Global Life Sciences Industry Outlook, 2018 report finds that healthcare digitization and consumerization, the explosion of patient data, and the emergence of
- Rare Pediatric Skin Conditions Often Get Expensive, Inconsistent Carehttps://practicaldermatology.com/news/rare-pediatric-skin-conditions-often-get-expensive-inconsistent-care/2457704/Children with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have high rates of complications — resulting in long and costly hospital stays — and that treatment strategies varied among health care providers, according to the first large-scale analysis, which is
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod